Socio-economic burden of disease: survivorship costs for renal cell carcinoma
Objective The objective of this study is to assess the risk-stratified 10-year socio-economic burden of renal cell carcinoma (RCC) follow-up costs after initial treatment in Germany from 2000 to 2020. Methods A micro-costing method considering direct and indirect medical expenditure associated with...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 2022
|
| In: |
European journal of cancer care
Year: 2022, Volume: 31, Issue: 3, Pages: 1-11 |
| ISSN: | 1365-2354 |
| DOI: | 10.1111/ecc.13569 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1111/ecc.13569 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1111/ecc.13569 
|
| Author Notes: | Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli |
| Summary: | Objective The objective of this study is to assess the risk-stratified 10-year socio-economic burden of renal cell carcinoma (RCC) follow-up costs after initial treatment in Germany from 2000 to 2020. Methods A micro-costing method considering direct and indirect medical expenditure associated with follow-up procedures was employed to calculate survivorship costs per patient. The frequencies of physician-patient visits, examinations and diagnostic tests were extracted from guidelines, whilst expenses were sourced from literature and official scales of tariffs. Societal costs were calculated based on three perspectives: patients, providers and insurers. Results Mean societal 10-year follow-up costs per patient amounted to EUR 3,377 (95%CI: 2,969-3,791) for low-risk, EUR 3,367 (95%CI: 3,003-3,692) for medium-risk and EUR 4,299 (95%CI: 3,807-4,755) for high-risk RCC in 2020. Spending increased by +32% from 2000 to 2020 for low-risk RCC, whilst medium-and high-risk RCC expenditure was cut by −39% and −22%, respectively. Patients shouldered 27%, providers 43% and insurers 35% of costs in 2020. Resources were consumed by medical imaging (52%), physician-patient consultations (31%), travel expenses (17%) and blood tests (1%). Conclusion Results highlight the economic burden cancer survivorship poses for society. Cancer survivors require individualised, evidence-based and insurance-covered follow-up schedules to permit the early detection of side-effects, metastasis and secondary malignancies. |
|---|---|
| Item Description: | Erstmals veröffentlicht: 15. März 2022 Gesehen am 27.02.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1365-2354 |
| DOI: | 10.1111/ecc.13569 |